{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T15:57:52Z","timestamp":1713369472869},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T00:00:00Z","timestamp":1481587200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00508-016-1120-8","type":"journal-article","created":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T12:31:47Z","timestamp":1481632307000},"page":"293-302","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement"],"prefix":"10.1007","volume":"129","author":[{"given":"Thamer","family":"Sliwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Beham-Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Burgstaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronika","family":"Buxhofer-Ausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnther","family":"Gastl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Krauth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Krippl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alois","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"W\u00f6hrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"W\u00f6lfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,13]]},"reference":[{"issue":"2","key":"1120_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.cytogfr.2013.01.004","volume":"24","author":"HC Hasselbalch","year":"2013","unstructured":"Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev. 2013;24(2):133\u201345. doi: 10.1016\/j.cytogfr.2013.01.004 .","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"1120_CR2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/leu.2015.360","volume":"30","author":"H Gisslinger","year":"2016","unstructured":"Gisslinger H, Jeryczynski G, Gisslinger B, Wolfler A, Burgstaller S, Buxhofer-Ausch V, et al. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia. 2016;30(5):1126\u201332.","journal-title":"Leukemia"},{"issue":"21","key":"1120_CR3","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","volume":"117","author":"J Thiele","year":"2011","unstructured":"Thiele J, Kvasnicka HM, Mullauer L, Buxhofer-Ausch V, Gisslinger B, Gisslinger H. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117(21):5710\u20138.","journal-title":"Blood"},{"issue":"2","key":"1120_CR4","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.beha.2014.07.004","volume":"27","author":"G Barosi","year":"2014","unstructured":"Barosi G. Essential thrombocythemia vs. early\/prefibrotic myelofibrosis: why does it matter. Best Pract Res Clin Haematol. 2014;27(2):129\u201340.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1120_CR5","unstructured":"Grie\u00dfhammer M, Baerlocher G, Gisslinger H, Lengfelder E, Petrides PE. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/primaere-myelofibrose-pmf\/@@view\/html\/index.html . Accessed May 11, 2016."},{"issue":"17","key":"1120_CR6","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u201390.","journal-title":"N Engl J Med"},{"issue":"25","key":"1120_CR7","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et\u00a0al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u201390.","journal-title":"N Engl J Med"},{"issue":"4","key":"1120_CR8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s11899-015-0278-x","volume":"10","author":"X Cahu","year":"2015","unstructured":"Cahu X, Constantinescu SN. Oncogenic drivers in myeloproliferative neoplasms: from JAK2 to calreticulin mutations. Curr Hematol Malig Rep. 2015;10(4):335\u201343.","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"1120_CR9","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","volume":"3","author":"Y Pikman","year":"2006","unstructured":"Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et\u00a0al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. Plos Med. 2006;3(7):e270.","journal-title":"Plos Med"},{"issue":"7","key":"1120_CR10","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472\u20137.","journal-title":"Leukemia"},{"issue":"3","key":"1120_CR11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","volume":"127","author":"JD Milosevic Feenstra","year":"2016","unstructured":"Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127(3):325\u201332.","journal-title":"Blood"},{"issue":"4459634","key":"1120_CR12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/JBM.S78826","volume":"6","author":"I Yonal-Hindilerden","year":"2015","unstructured":"Yonal-Hindilerden I, Daglar-Aday A, Akadam-Teker B, Yilmaz C, Nalcaci M, Yavuz AS, et al. Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms. J Blood Med. 2015;6(4459634):157\u201375.","journal-title":"J Blood Med"},{"issue":"3912063","key":"1120_CR13","first-page":"89","volume":"7","author":"TI Mughal","year":"2014","unstructured":"Mughal TI, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7(3912063):89\u2013101.","journal-title":"Int J Gen Med"},{"issue":"9","key":"1120_CR14","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3324\/haematol.2014.119545","volume":"100","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. Haematologica. 2015;100(9):1139\u201345.","journal-title":"Haematologica"},{"key":"1120_CR15","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016;9:18.","journal-title":"J Hematol Oncol"},{"issue":"33","key":"1120_CR16","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","volume":"30","author":"RM Emanuel","year":"2012","unstructured":"Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et\u00a0al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J\u00a0Clin Oncol. 2012;30(33):4098\u2013103.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1120_CR17","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/leu.2013.74","volume":"27","author":"T Barbui","year":"2013","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A. Problems and pitfalls regarding WHO-defined diagnosis of early\/prefibrotic primary myelofibrosis versus essential thrombocythemia. Leukemia. 2013;27(10):1953\u20138.","journal-title":"Leukemia"},{"issue":"6","key":"1120_CR18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/his.12871","volume":"68","author":"HM Kvasnicka","year":"2016","unstructured":"Kvasnicka HM, Beham-Schmid C, Bob R, Dirnhofer S, Hussein K, Kreipe H, et al. Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis \u2013 a consensus-based study. Histopathology. 2016;68(6):905\u201315.","journal-title":"Histopathology"},{"issue":"20","key":"1120_CR19","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et\u00a0al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"5","key":"1120_CR20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et\u00a0al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937\u201351.","journal-title":"Blood"},{"issue":"4558589","key":"1120_CR21","doi-asserted-by":"crossref","first-page":"e337","DOI":"10.1038\/bcj.2015.64","volume":"5","author":"T Barbui","year":"2015","unstructured":"Barbui T, Thiele J, Vannucchi AM, Tefferi A. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis. Blood Cancer J. 2015;5(4558589):e337.","journal-title":"Blood Cancer J"},{"issue":"2","key":"1120_CR22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008;22(2):437\u20138.","journal-title":"Leukemia"},{"key":"1120_CR23","doi-asserted-by":"crossref","first-page":"102476","DOI":"10.1155\/2015\/102476","volume":"2015","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC, Bjorn ME. MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediators Inflamm. 2015;2015:102476.","journal-title":"Mediators Inflamm."},{"issue":"2","key":"1120_CR24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/ajh.23384","volume":"88","author":"A Tefferi","year":"2013","unstructured":"Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol. 2013;88(2):141\u201350.","journal-title":"Am J Hematol"},{"issue":"13","key":"1120_CR25","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et\u00a0al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895\u2013901.","journal-title":"Blood"},{"issue":"7","key":"1120_CR26","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia. 2014;28(7):1494\u2013500.","journal-title":"Leukemia"},{"key":"1120_CR27","first-page":"Abstract #405","volume-title":"Mutation-Enhanced International Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT project","author":"AMGP Vannucchi","year":"2014","unstructured":"Vannucchi AMGP, Rotunno G. Mutation-Enhanced International Prognostic Scoring System (MIPSS) for primary myelofibrosis: an AGIMM & IWG-MRT project. American Society of Hematology (ASH) Annual Meeting, San Francisco. 2014, p Abstract #405."},{"issue":"11","key":"1120_CR28","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/leu.2015.233","volume":"29","author":"NM Kroger","year":"2015","unstructured":"Kroger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, Barbui T, et\u00a0al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT\/ELN international working group. Leukemia. 2015;29(11):2126\u201333.","journal-title":"Leukemia"},{"issue":"21","key":"1120_CR29","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1182\/blood-2014-10-608315","volume":"125","author":"N Kroger","year":"2015","unstructured":"Kroger N, Giorgino T, Scott BL, Ditschkowski M, Alchalby H, Cervantes F, et\u00a0al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015;125(21):3347\u201350, quiz 64.","journal-title":"Blood"},{"issue":"9","key":"1120_CR30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"issue":"9","key":"1120_CR31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787\u201398.","journal-title":"N Engl J Med"},{"key":"1120_CR32","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/leu.2016.148","volume":"30","author":"CN Harrison","year":"2016","unstructured":"Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30:1701. doi: 10.1038\/leu.2016.148 .","journal-title":"Leukemia"},{"key":"1120_CR33","unstructured":"Verstovsek SMR, Gotlib J. et al. Long-term outcomes of ruxolitinib therapy in patients with myelofibrosis: 5\u2011year final efficacy and safety analysis from COMFORT-I. 2016 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meeting, Copenhagen, 9.-12. Jun 2016. : ; 2016, p Abstract #S452."},{"issue":"3","key":"1120_CR34","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.bbmt.2015.10.005","volume":"22","author":"M Shanavas","year":"2016","unstructured":"Shanavas M, Popat U, Michaelis LC, Fauble V, McLornan D, Klisovic R, et\u00a0al. Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis with prior exposure to Janus Kinase 1\/2 inhibitors. Biol Blood Marrow Transplant. 2016;22(3):432\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"1120_CR35","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/leu.2015.212","volume":"29","author":"R Zeiser","year":"2015","unstructured":"Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29(10):2062\u20138.","journal-title":"Leukemia"},{"issue":"2","key":"1120_CR36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/bmt.2013.173","volume":"49","author":"N Jaekel","year":"2014","unstructured":"Jaekel N, Behre G, Behning A, Wickenhauser C, Lange T, Niederwieser D, et\u00a0al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant. 2014;49(2):179\u201384.","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"1120_CR37","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3109\/10428194.2014.916805","volume":"56","author":"A Tabarroki","year":"2015","unstructured":"Tabarroki A, Saunthararajah Y, Visconte V, Cinalli T, Colaluca K, Rogers HJ, et\u00a0al. Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts. Leuk Lymphoma. 2015;56(2):497\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"1120_CR38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1756-8722-6-81","volume":"6","author":"M Talpaz","year":"2013","unstructured":"Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, et\u00a0al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J\u00a0Hematol Oncol. 2013;6(1):81.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1120_CR39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/10428194.2015.1046867","volume":"57","author":"ME Bjorn","year":"2016","unstructured":"Bjorn ME, Holmstrom MO, Hasselbalch HC. Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients. Leuk Lymphoma. 2016;57(1):125\u20138.","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"1120_CR40","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86(12):1188\u201391.","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"1120_CR41","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/cncr.22021","volume":"107","author":"RA Mesa","year":"2006","unstructured":"Mesa RA, Nagorney DS, Schwager S, Allred J, Tefferi A. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer. 2006;107(2):361\u201370.","journal-title":"Cancer"},{"issue":"12","key":"1120_CR42","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00277-010-1019-9","volume":"89","author":"A Martinez-Trillos","year":"2010","unstructured":"Martinez-Trillos A, Gaya A, Maffioli M, Arellano-Rodrigo E, Calvo X, Diaz-Beya M, et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol. 2010;89(12):1233\u20137.","journal-title":"Ann Hematol"},{"key":"1120_CR43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-015-0021-2","volume":"4","author":"MF McMullin","year":"2015","unstructured":"McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jakel N, Gopalakrishna P, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol. 2015;4:26.","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"1120_CR44","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00277-015-2435-7","volume":"94","author":"F Cervantes","year":"2015","unstructured":"Cervantes F, Isola IM, Alvarez-Larran A, Hernandez-Boluda JC, Correa JG, Pereira A. Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. Ann Hematol. 2015;94(11):1791\u20136.","journal-title":"Ann Hematol"},{"issue":"2","key":"1120_CR45","first-page":"105","volume":"63","author":"MS Hertzberg","year":"2000","unstructured":"Hertzberg MS, Wong M. Hypercalcemia and adrenal insufficiency in a patient with myelofibrosis. Am J Hematol. 2000;63(2):105.","journal-title":"Am J Hematol"},{"issue":"27","key":"1120_CR46","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2008.21.7356","volume":"27","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Verstovsek S, Barosi G, Passamonti F, Roboz GJ, Gisslinger H, et\u00a0al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J\u00a0Clin Oncol. 2009;27(27):4563\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1120_CR47","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/leu.2014.306","volume":"29","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Abdelrahman RA, Finke C, Lasho TT, Begna KH, Al-Kali A, et al. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis. Leukemia. 2015;29(3):741\u20134.","journal-title":"Leukemia"},{"issue":"20","key":"1120_CR48","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.2217\/fon.15.200","volume":"11","author":"S Verstovsek","year":"2015","unstructured":"Verstovsek S, Komrokji RS. A comprehensive review of pacritinib in myelofibrosis. Future Oncol. 2015;11(20):2819\u201330.","journal-title":"Future Oncol"},{"key":"1120_CR49","first-page":"Abstract # 823","volume-title":"5-Azacitidine (AZA) in combination with ruxolitinib (RUX) as therapy for patients with myelodysplastic\/myeloproliferative neoplasms (MDS\/MPNS)","author":"N Daver","year":"2015","unstructured":"Daver N, G\u2011MG, Cortes JE. et al. 5\u2011Azacitidine (AZA) in combination with ruxolitinib (RUX) as therapy for patients with myelodysplastic\/myeloproliferative neoplasms (MDS\/MPNS). American Society of Hematology (ASH) Annual Meeting, Orlando. 2015, p Abstract # 823."},{"issue":"6","key":"1120_CR50","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/bjh.12459","volume":"162","author":"JC Ianotto","year":"2013","unstructured":"Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, et al. Efficacy and safety of pegylated-interferon alpha-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. Br J Haematol. 2013;162(6):783\u201391.","journal-title":"Br J Haematol"},{"issue":"12","key":"1120_CR51","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s002770050554","volume":"78","author":"T Bachleitner-Hofmann","year":"1999","unstructured":"Bachleitner-Hofmann T, Gisslinger H. The role of interferon-alpha in the treatment of idiopathic myelofibrosis. Ann Hematol. 1999;78(12):533\u20138.","journal-title":"Ann Hematol"},{"key":"1120_CR52","first-page":"Abstract # 2803","volume-title":"Long term follow up of a phase 2 study of ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm","author":"LPC Pieri","year":"2015","unstructured":"Pieri LPC, Arena U. et\u00a0al. Long term follow up of a phase 2 study of ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm. American Society of Hematology (ASH) Annual Meeting, Orlando. 2015, p Abstract # 2803."},{"issue":"1","key":"1120_CR53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2013.235","volume":"28","author":"G Caocci","year":"2014","unstructured":"Caocci G, Murgia F, Podda L, Solinas A, Atzeni S, La Nasa G. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia. 2014;28(1):225\u20137.","journal-title":"Leukemia"},{"issue":"8","key":"1120_CR54","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/leu.2014.104","volume":"28","author":"RK Hopman","year":"2014","unstructured":"Hopman RK, Lawrence SJ, Oh ST. Disseminated tuberculosis associated with ruxolitinib. Leukemia. 2014;28(8):1750\u20131.","journal-title":"Leukemia"},{"issue":"Suppl 3","key":"1120_CR55","doi-asserted-by":"crossref","first-page":"iii57","DOI":"10.1093\/annonc\/mdu180","volume":"25","author":"P Fenaux","year":"2014","unstructured":"Fenaux P, Haase D, Sanz GF, Santini V, Buske C, Group EGW. Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii57\u2013iii69.","journal-title":"Ann Oncol"},{"issue":"3","key":"1120_CR56","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjh.12985","volume":"167","author":"JT Reilly","year":"2014","unstructured":"Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, et\u00a0al. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Br J Haematol. 2014;167(3):418\u201320.","journal-title":"Br J Haematol"},{"issue":"Suppl 5","key":"1120_CR57","doi-asserted-by":"crossref","first-page":"v85","DOI":"10.1093\/annonc\/mdv203","volume":"26","author":"AM Vannucchi","year":"2015","unstructured":"Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kroger N, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v85\u2013v99.","journal-title":"Ann Oncol"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-016-1120-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-016-1120-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-016-1120-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T13:22:10Z","timestamp":1568640130000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-016-1120-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,13]]},"references-count":57,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["1120"],"URL":"https:\/\/doi.org\/10.1007\/s00508-016-1120-8","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,13]]}}}